Ondansetron

Pruritus, Hyperemesis Gravidarum, Nausea + 8 more

Treatment

4 Active Studies for Ondansetron

What is Ondansetron

Ondansetron

The Generic name of this drug

Treatment Summary

Ondansetron is a drug used to treat nausea and vomiting caused by chemotherapy drugs like cisplatin. It is also known to have calming and anti-psychotic effects. Developed in the 1980s by GlaxoSmithKline and approved by the FDA in 1991, ondansetron comes in oral tablets, dissolving tablets, and injections, and generic versions are also available. Recently, an orally soluble film version was developed that is easier to take and hides discreetly.

Zofran

is the brand name

Ondansetron Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zofran

Ondansetron

1991

583

Effectiveness

How Ondansetron Affects Patients

Ondansetron is a medication that prevents nausea and vomiting. It works by blocking serotonin receptors in the brain and GI tract, which then stops the reflex that causes these symptoms. When taken intravenously, high doses of this drug can lead to an abnormal heart rhythm called QT prolongation. However, when taken orally, this drug is not thought to cause this side effect. Other effects of ondansetron include slowing down colonic transit and having no effect on plasma prolactin concentrations.

How Ondansetron works in the body

Ondansetron works by blocking serotonin receptors, which help to regulate the vomiting reflex. This reflex is triggered by the release of serotonin from cells in the small intestine. Ondansetron works to prevent this reflex, likely by blocking serotonin receptors located in the peripheral or central nervous systems. We don't know for sure how ondansetron works to prevent vomiting from opiates, but it likely works in a similar way.

When to interrupt dosage

The measure of Ondansetron is contingent upon the diagnosed status, including Uremia, radiation therapy caused nausea and vomiting and Pharmacotherapy. The extent of dosage may be found in the table beneath, based on the method of administration.

Condition

Dosage

Administration

Pharmacotherapy

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Uremia

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Pharmacotherapy

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Malignant Neoplasms

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Pruritus

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Hyperemesis Gravidarum

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

radiation therapy induced nausea and vomiting

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Nausea

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Malignant Neoplasms

3.2 mg/mL, , 2.0 mg/mL, 8.0 mg, 4.0 mg, 24.0 mg, 4.0 mg/mL, 0.4 mg, 16.0 mg, 2.0 mg, 8.0 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated - Oral, Oral, Tablet, film coated, Tablet, Tablet - Oral, Tablet, orally disintegrating - Oral, Solution, Solution - Oral, Tablet, coated, Solution - Intramuscular; Intravenous, Solution - Intravenous, Liquid, Liquid - Intravenous, Film - Oral, Film, Tablet, orally disintegrating, Injection - Intravenous, Sublingual, Troche, Troche - Sublingual, Tablet, coated - Oral, Intramuscular, Injection, solution - Intramuscular, Film, soluble - Oral, Film, soluble

Warnings

Ondansetron Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ondansetron.

Common Ondansetron Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Ondansetron.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Ondansetron.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Anagrelide.

Apomorphine

Major

The risk or severity of adverse effects can be increased when Ondansetron is combined with Apomorphine.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Arsenic trioxide.

Ondansetron Toxicity & Overdose Risk

Taking too much ondansetron may lead to unexpected side effects such as temporary blindness, low blood pressure, abnormal heart rhythms, neurological problems, and seizures. There is also not enough information to safely recommend taking ondansetron during pregnancy or while breastfeeding, or for children 3 years of age or younger.

Ondansetron Novel Uses: Which Conditions Have a Clinical Trial Featuring Ondansetron?

Two active studies are presently exploring the potential of Ondansetron to reduce Nausea, Uremia and radiation therapy induced emesis.

Condition

Clinical Trials

Trial Phases

Hyperemesis Gravidarum

0 Actively Recruiting

Nausea

0 Actively Recruiting

radiation therapy induced nausea and vomiting

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Nausea

3 Actively Recruiting

Phase 2, Not Applicable, Phase 3

Nausea

0 Actively Recruiting

Pruritus

0 Actively Recruiting

Pharmacotherapy

0 Actively Recruiting

Uremia

0 Actively Recruiting

Pharmacotherapy

1 Actively Recruiting

Not Applicable

Malignant Neoplasms

0 Actively Recruiting

Patient Q&A Section about ondansetron

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ondansetron mainly used for?

"Ondansetron is a medication used to prevent nausea and vomiting. It is in a class of medications called serotonin 5-HT3 receptor antagonists. Ondansetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting."

Answered by AI

Is ondansetron 4mg a narcotic?

"Zofran is not a narcotic; it is a 5-HT3 (serotonin) receptor antagonist."

Answered by AI

How long does it take for ondansetron to kick in?

"ODT: Put the tablet on your tongue and wait for it to dissolve.

Ondansetron can be taken with or without food. For tablets, swallow with a glass of water. For ODT, put on tongue and wait for it to dissolve. It starts to work within 30 minutes to an hour."

Answered by AI

Is ondansetron used for anxiety?

"The study concludes that ondansetron is an effective treatment against early onset alcoholism, and that it may also help to relieve symptoms of depression and anxiety."

Answered by AI

Clinical Trials for Ondansetron

Image of Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Canada.

Aprepitant for Postoperative Nausea and Vomiting

18+
All Sexes
Montreal, Canada

Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.

Phase 3
Waitlist Available

Centre hospitalier de l'Université de Montréal (CHUM)

Maxim Roy, MD, FRCPC

Image of Endeavor Health in Evanston, United States.

Autonomic Neural Blockade for Postoperative Symptoms in Bariatric Surgery

18 - 90
All Sexes
Evanston, IL

The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain/nausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.

Waitlist Available
Has No Placebo

Endeavor Health

Herbert Hedberg, MD

Image of The Hospital for Sick Children in Toronto, Canada.

ML-Based Intervention for Vomiting in Pediatric Cancer

Any Age
All Sexes
Toronto, Canada

The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients. The main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will: Primary 1\. Reduce the proportion with any vomiting within the 96-hour window Secondary 1. Reduce the number of vomiting episodes 2. Increase the proportion receiving care pathway-consistent care 3. Impact on number of administrations and costs of antiemetic medications Newly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.

Recruiting
Has No Placebo

The Hospital for Sick Children

Santiago Arciniegas, MSc